Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 28, 2014; 20(32): 11376-11383
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11376
Published online Aug 28, 2014. doi: 10.3748/wjg.v20.i32.11376
Laparoscopic spleen-preserving splenic hilar lymphadenectomy in 108 consecutive patients with upper gastric cancer
Ping Li, Chang-Ming Huang, Chao-Hui Zheng, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Yi Wang, Qi-Yue Chen, Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China
Author contributions: Li P, Huang CM and Zheng CH conceived the study, analysed the data, and drafted the manuscript; Xie JW helped to critically revise the manuscript for important intellectual content; Wang JB, Lin JX, Lu J, Wang Y, and Chen QY helped collect the data and design the study; all authors read and approved the final manuscript.
Supported by the National Key Clinical Specialty Discipline Construction Program of China, No. [2012]649
Correspondence to: Chang-Ming Huang, Professor, Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, Fujian Province, China. hcmlr2002@163.com
Telephone: +86-591-83363366 Fax: +86-591-83320319
Received: January 8, 2014
Revised: April 12, 2014
Accepted: July 24, 2014
Published online: August 28, 2014
Revised: April 12, 2014
Accepted: July 24, 2014
Published online: August 28, 2014
Core Tip
Core tip: Several studies have shown that laparoscopic spleen-preserving No. 10 lymphadenectomy is feasible for patients with upper gastric cancer; however, the sample sizes in these studies were small. Thus, the value of the procedure must be further evaluated with large sample studies, and it is debatable whether routine No. 10 lymphadenectomy should be performed for advanced upper gastric cancer (AUGC) without serosa invasion. Therefore, we evaluated the feasibility and short-term efficacy of laparoscopic spleen-preserving No. 10 lymphadenectomy in 108 consecutive patients with AUGC (cT2-3). In addition, early follow-up results were also presented.